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Open access undThe primary treatment goal of radiotherapy for paragangliomas of the head and neck region (HNPGLs) is
local control of the tumor, i.e. stabilization of tumor volume. Interestingly, regression of tumor volume
has also been reported. Up to the present, no meta-analysis has been performed giving an overview of
regression rates after radiotherapy in HNPGLs. The main objective was to perform a systematic review
and meta-analysis to assess regression of tumor volume in HNPGL-patients after radiotherapy. A second
outcome was local tumor control. Design of the study is systematic review and meta-analysis. PubMed,
EMBASE, Web of Science, COCHRANE and Academic Search Premier and references of key articles were
searched in March 2012 to identify potentially relevant studies. Considering the indolent course of
HNPGLs, only studies withP12 months follow-up were eligible. Main outcomes were the pooled propor-
tions of regression and local control after radiotherapy as initial, combined (i.e. directly post-operatively
or post-embolization) or salvage treatment (i.e. after initial treatment has failed) for HNPGLs. A meta-
analysis was performed with an exact likelihood approach using a logistic regression with a random
effect at the study level. Pooled proportions with 95% conﬁdence intervals (CI) were reported. Fifteen
studies were included, concerning a total of 283 jugulotympanic HNPGLs in 276 patients. Pooled regres-
sion proportions for initial, combined and salvage treatment were respectively 21%, 33% and 52% in radi-
osurgery studies and 4%, 0% and 64% in external beam radiotherapy studies. Pooled local control
proportions for radiotherapy as initial, combined and salvage treatment ranged from 79% to 100%. Radio-
therapy for jugulotympanic paragangliomas results in excellent local tumor control and therefore is a
valuable treatment for these types of tumors. The effects of radiotherapy on regression of tumor volume
remain ambiguous, although the data suggest that regression can be achieved at least in some patients.
More research is needed to identify predictors for treatment success.
 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 106 (2013) 161–168Head and neck paragangliomas (HNPGLs) are rare tumors of par-
aganglia. They consist of chromafﬁn tissue and are associated with
the parasympathetic autonomic nervous system. HNPGLs are
named according to site of origin. The most common HNPGLs are
the carotid body tumor, vagal body tumor and jugulotympanic tu-
mor (i.e. paraganglioma of the temporal bone) [1,2]. Due to their
location in close proximity to important neurovascular structures,
tumor growth may lead to serious morbidity and cranial nerve
impairment, however the majority of HNPGLs are notoriously be-
nign, indolent tumors and a ‘‘wait and scan’’ policymay be advisable
in appropriate cases [2,3]. Therefore, if treatment is commenced, this
should focus on reducingmorbidity rather than increasing survival.
With surgical treatment, it is possible to remove the tumor
without recurrence. Surgery however, leads to neurovascularndocrinology and Metabolic
9600, 2300 RC Leiden, The
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er CC BY-NC-ND license.complications in up to 60% of cases; especially cranial nerve injury
and, less frequently, carotid artery lesions [4,5]. Radiotherapy is an
alternative treatment in HNPGL-patients. Irradiation produces
ﬁbrosis and vascular sclerosis rather than eradication of the tumor
cells [6,7]. Its main objective is long-term local control, i.e. no pro-
gression of tumor volume. Interestingly, it can also lead to tumor
regression, which may result in reduction of HNPGL-associated
symptoms [8,9].
The effect of radiation is difﬁcult to assess given the indolent
natural course of HNPGLs. Only long-term follow-up might provide
evidence that radiotherapy is a beneﬁcial treatment in these pa-
tients. Since HNPGLs almost never show spontaneous tumor vol-
ume reduction, tumor regression is probably a better marker for
radiotherapy effect than local tumor control.
Objective of the study
A few systematic reviews and meta-analyses of the effects of
radiotherapy on HNPGLs have been published [10–12]. However,
162 Radiotherapy for jugulotympanic paragangliomasthese reviews assessed the effect of radiotherapy by local control
rates rather than regression rates and up until now, a meta-analy-
sis assessing regression of tumor volume has not been performed.
The main aim of the present study was to perform a comprehen-
sive systematic review and meta-analysis of tumor regression fol-
lowing different types of radiotherapy in HNPGLs.
Materials and methods
Eligibility criteria
Studies assessing the effect of radiotherapy on tumor volume of
HNPGLs were eligible for inclusion. The analysis aimed to assess
the proportion of HNPGL-patients with tumor regression after
radiotherapy, with local control rates as second outcome. Accord-
ing to the ‘‘Response evaluation in solid tumors (RECIST) criteria’’,
a partial treatment response is deﬁned as ‘‘at least a 30% decrease
in the sum of diameters of target lesions, taking as reference the
baseline sum diameters’’ [13]. However, the RECIST criteria have
not (yet) been widely accepted in the ﬁeld of paragangliomas.
More importantly, the primary intention of treatment for HNPGLs
is to reduce morbidity and relief of HNPGL-associated symptoms
has been observed after a regression of tumor volume of less than
30% [8,14]. In view of this clinical relevance, we broadened our def-
inition and deﬁned tumor regression as any tumor volume less
than the tumor volume before radiotherapy. Local control was de-
ﬁned as a tumor volume equal to or less than the tumor volume at
start of radiotherapy.
We aimed to stratify tumor regression and local control rates
for radiotherapy as initial treatment (i.e. without prior therapy),
combined treatment (i.e. directly post-operatively or post-
embolization) or salvage treatment (i.e. after initial treatment
has failed). Studies regarding radiotherapy preoperatively were
not included. In addition, we tried to stratify for type of radiother-
apy (i.e. radiosurgery/stereotactic radiotherapy (RS) or external
beam radiotherapy (EBRT)). In our analyses, we combined the
results of the two types of high precision radiotherapy: stereotactic
radiotherapy and radiosurgery.
To accurately assess regression and local control rates, ﬁrstly,
only studies determining treatment response (tumor volume) by
radiologic evaluation were eligible for inclusion. Secondly, consid-
ering the indolent nature of HNPGLs [3], only studies with
P12 months follow-up were eligible.
Studies concerning patients with malignant HNPGLs were ex-
cluded, unless data for patients with benign HNPGLs could be ex-
tracted separately. We deﬁned malignant HNPGL as the presence
of metastases, i.e. the presence of chromafﬁn tissue in nonchrom-
afﬁn organs, distant from the primary tumor [15–17].
In case of multiple studies describing the same cohort, the study
which comprised the highest number of subjects and/or the lon-
gest duration of follow-up was included. Furthermore, only studies
reporting a population of more than 10 HNPGL-patients were in-
cluded. Eligible studies were restricted to languages familiar to
the authors (English, French, German and Dutch). When reported
data were not sufﬁcient for accurate data extraction, we tried to
contact the authors for clariﬁcation.
Search strategy
In March 2012, PubMed, EMBASE, Web of Science, COCHRANE
and Academic Search Premier were searched to identify potentially
relevant studies (Appendix 1). References of key articles were as-
sessed for additional relevant articles.
Data extraction
All studies obtained from the search strategy were entered into
reference manager software (Reference Manager version 12,Thomson Reuters, Philadelphia, PA) and were screened on title
and abstract. Potentially relevant studies were retrieved for de-
tailed assessment. For eligible studies, data were independently
extracted by two reviewers (L.v.H. and E.C.). Disagreements be-
tween reviewers were resolved by consensus, but when doubt re-
mained, a third reviewer (O.D.) decided.Risk of bias assessment
The present meta-analysis is based on observational studies.
Risk of bias assessment was based on study components that
potentially bias an association between the intervention under
study (radiotherapy) and the outcomes (regression and local con-
trol). The following elements were assessed for all studies:
1. Risk of selection bias. Inclusion of consecutive exposed patients
or a random sample of the inception cohort was considered a
low risk of bias.
2. Adequacy of reporting of intervention (radiotherapy). When
type and dose of radiotherapy were reported, this was consid-
ered adequate.
3. Adequacy of measurements for regression and local control. The
effect of radiotherapy on tumor volume should have been mea-
sured by either sequential MRI or CT scanning.
4. Adequacy of result stratiﬁcation per treatment modality (i.e.
initial, combined or salvage treatment).
5. Adequacy of follow-up. Loss to follow-up <5% was considered to
represent a low risk of bias.
Statistical analysis
The main outcome of the present meta-analysis was the pooled
proportion of HNPGLs with regression after radiotherapy. The
pooled proportion of HNPGLs with local control after radiotherapy
was the secondary outcome. For all studies, the proportion of
HNPGLs with tumor regression was calculated as the number of
HNPGLs with tumor regression divided by the total number
of HNPGLs treated with radiotherapy. The same procedure was
applied to the proportion of HNPGLs with local control. For all pro-
portions exact 95% conﬁdence intervals (95% CI) were calculated.
Meta-analysis was performed using an exact likelihood ap-
proach. The method used was a logistic regression with a random
effect at the study level. Given the expected clinical heterogeneity
a random effects model was performed by default and no ﬁxed ef-
fects analyses were performed. For meta-analysis of proportions
the exact likelihood approach based on a binomial distribution
has advantages compared to a standard (DerSimonian and Laird)
random effects model that is based on normal distributions. Firstly,
estimates from a binomial model are less biased than estimates
from models based on a normal approximation. This is especially
the case for proportions that are close to 0 or 1. Secondly, no
assumptions are needed for the exact approximation when dealing
with zero-cells, whereas the standard approach needs to add an
arbitrary value (often 0.5) when dealing with zero-cells. Adding
values to zero-cells is known to contribute to the biased estimate
of the model. All analyses were performed with STATA 12.0 (Stata
Corp., Texas, USA).Results
Study selection
The initial search resulted in 1371 unique records; 137 were se-
lected for detailed assessment (Fig. 1). After detailed assessment,
122 articles were excluded for following reasons: no original data
(n = 4), no radiologic evaluation (n = 51), inclusion of patients with
1371 potentially relevant 
electronic search
137 publications retrieved 
for detailed assessment
15 studies included in 
the meta-analysis
122 studies not included for 
following reasons:
- no adequate radiologic 
  evaluation (51)
- inclusion of patients with 
  < 12 months follow-up (14)
- inclusion of patients with 
  malignant HNPGL (4)
- outcome other than local 
  control (19)
- no original data (4)
- proportion of patients 
  < 10 (26)
- cohort already reported (4)
publications identified from
Fig. 1. Flow-diagram of search strategy and study selection.
Table 1
Characteristics of included studies.
First author
(year of
publication)
Tumor
localization
(n patients)
Mean age
in years
Treatment
modality
(n)
Type
of RT
(n)
Dose of RT Me
tum
vol
cc
bas
(ra
Lee (2011)
[31]
JT (14) Median
42.3
(range
22.1–68.9)
Initial (9)
Salvage (5)
RS
(14)
Mean dose-
to-the-tumor
margin
13.7 Gy
(range 12.5–
15.0)
9.5
22.
Chen
(2010)
[25]
JT (13)a 61.8 ± 14.5 Initial (9)
Salvage (4)
RS
(13)
Mean dose-
to-the-tumor
margin
14.6 ± 1.5 Gy
(range 12–
16)
5.9
17.
Genc (2010)
[14]
JT (18) 49.6 ± 14.6 Initial (7)
Salvage
(11)
RS
(18)
Mean dose-
to-the-tumor
margin
15.6 Gy
(range 13–
20)
5.5
98.
Hafez
(2010)
[28]
JT (13) 43.6 Initial (11)
Salvage (2)
RS
(13)
Dose-to-the-
tumor
margin range
12–15 Gy
Me
Tran Ba Huy
(2009)
[30]
JT (45
tumors in
41 patients)
59.5 Initial (41) EBRT
(41)
Mean total
dose 45 Gy
(range 44–
50)
n.r.
Henzel
(2007)
[29]
JT (17) Median 65
(range 30–
82)
Initial (6)
Salvage
(11)
SR
(17)
Median
cumulative
dose 57 Gy
(range 52.5–
65)
7.4
26.
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nant HNPGL (n = 4), outcome other than local control or regression
(n = 19), results reported for less than 10 patients (n = 26). Further-
more, four studies comprised a cohort also described in another
publication; the studies with the smallest sample sizes were ex-
cluded [18–21]. No new articles were found in references of key
articles. Finally, a total of 15 studies were included in the present
analysis, three written in French [22–24] and 12 in English
[8,14,25–34].
Study characteristics
Study characteristics are displayed in Table 1. Included studies
were published from 1986 to 2011. All included studies were clas-
siﬁed as cohort studies [35].
A total of 276 patients with 283 HNPGLs were included in this
meta-analysis. The largest study contained 41 subjects [30]. Mean
age ranged from 42 to 66 years. Mean duration of follow-up ranged
from 39 to 137 months. All studies comprised patients with jugu-
lotympanic tumors only. One study also comprised one single pa-
tient with a thyroid paraganglioma [26].
Radiotherapy was performed as initial therapy in 14 studies
[8,14,22–25,27–34], as combined therapy in four [22,24,27,33]
and as salvage treatment in 12 [8,14,22,25–29,31–34]. In four
studies HNPGL-patients were treated with external beam radio-
therapy (EBRT) [22–24,30], in seven studies with radiosurgery
[8,14,25,27,28,31,32], and in two studies data of EBRT anddian
or
ume in
at
eline
nge)
Follow-up
imaging
Deﬁnition of regression Deﬁnition
of local
control
Mean
duration of
follow-up
(months)
(6.2–
1)
MRI Any decrease in tumor
volume
No
progression
in tumor
volume
Median
40.3 (range
13.2–143.7)
(0.88–
95)
n.s. 15% decrease in tumor
volume
<15%
progression
or a
decrease in
tumor
volume
49.1 ± 42.9
(2.0–
9)
MRI Any decrease in tumor
volume
No
progression
in tumor
volume
52.5 ± 33.0
an 8.4 MRI Any decrease in tumor
volume
Stable or
decreased
tumor
volume
Range 12–
48
CT and/or
MRI
P20% decrease in tumor
volume
No
progression
in tumor
volume
50
(0.1–
7)
MRI >2 mm reduction in
tumor diameter, 50%
reduction in tumor
dimension or 20%
reduction in
preradiosurgical volume
Stable or
decreased
tumor
volume
Median 40
(range 12–
84)
(continued on next page)
Table 1 (continued)
First author
(year of
publication)
Tumor
localization
(n patients)
Mean age
in years
Treatment
modality
(n)
Type
of RT
(n)
Dose of RT Median
tumor
volume in
cc at
baseline
(range)
Follow-up
imaging
Deﬁnition of regression Deﬁnition
of local
control
Mean
duration of
follow-up
(months)
Lim (2007)
[32]
JT (20
tumors in
17
patients)b
55.4 ± 19.7 Initial (16
tumors in
13
patients)
Salvage (4)
RS
(17)
Mean dose-
to-the-tumor
margin
20.5 ± 3.7 Gy
(range 14–
27)
2.8 (1.2–
6.2)
MRI Any decrease in tumor
volume
Stable or
decreased
tumor
volume
47.6 ± 43.4
Gerosa
(2006)
[8]
JT (20) 55.8 ± 11.6 Initial (3)
Salvage
(17)
RS
(20)
Mean dose-
to-the-tumor
margin
17.3 Gy
(range 13–
24)
Mean 7.0 MRI P20% decrease in tumor
volume
Unchanged
or
decreased
tumor
volume
50.9
Nguyen
(2005)
[23]
JT (14)c 65.9 ± 14.8 Initial (14) EBRT
(14)
Mean total
dose
52.9 ± 4.2 Gy
(range 45–
60)
n.r. CT n.r. No
progression
in tumor
volume
66.4 ± 48.5
Zabel
(2004)
[34]
JT (22) Median 58
(range 20–
80)
Initial (10)
Salvage
(12)
SR
(22)
Median total
dose 57.6 Gy
71.8
(10.5–
212.2)
MRI Any decrease in tumor
volume
Stable or
decreased
tumor
volume
Median
68.4 (19–
177)
Elshaikh
(2002)
[26]
JT (11)
TPGL (1)
n.r. Salvage
(12)
EBRT
(5)
RS
(7)
EBRT: dose-
to-the-tumor
margin range
45–54 Gy
RS: dose-to-
the-tumor
margin range
13–16 Gy
n.r. n.s. n.a. Stable or
decreased
tumor
volume
Median 39
(range 25–
114)
Eustacchio
(2002)
[27]
JT (18) Median 56
(range 21–
80)d
Initial (3)
Combined
(6)
Salvage (9)
RS
(18)
Median dose-
to-the-tumor
margin 14 Gy
(range 12–
20)
5.2 (0.4–
33.5)d
MRI, in
some cases
CT in
addition*
Any decrease in tumor
volume
Stable or
decreased
tumor
volume
Median
86.4 (range
18–120)
Saringer
(2002)
[33]
JT (33)e 61.5
(EBRT)
63.5 (RS)
Initial (9
EBRT, 6 RS)
Combined
(9 EBRT, 3
RS)
Salvage (6
RS)
EBRT
(18)
RS
(15)
EBRT:
median total
dose 46.8 Gy
(range 36–
52)
RS: median
maximal
dose 24 Gy
(range 20–
35)
n.r. MRI Any decrease in tumor
volume
No
progression
in tumor
volume
136.8
(initial
EBRT, six
patients)
102 (initial
EBRT, three
patients)
62.4 (initial
RS, six
patients)
99.6
(combined
EBRT, ﬁve
patients)
90
(combined
EBRT, four
patients)
73.2
(combined
RS, three
patients)
60 (salvage
RS, 6
patients)
Baillet
(1990)
[22]
JT (14) 59f Initial (6)
Combined
(3)
Salvage (5)
EBRT
(14)
Mean total
dose
50.6 ± 6.2 Gy
(range 45–
60)f
n.r. n.s. Any decrease in tumor
volume
No
progression
in tumor
volume
Range 24–
132f
Scherrer
(1986)
[24]
JT (10) Range 30–
70
Initial (8)
Combined
(2)
EBRT
(10)
Mean total
dose 50 Gy
(range 45–
60)
n.r. CT and/or
tomography
n.r. n.r. 104.4 ± 70.9
± = standard deviation, n.r. = not reported, n.s. = not speciﬁed, n.a. = not applicable, JT = jugulotympanic, TPGL = thyroid paraganglioma, RT = radiotherapy, EBRT = external
beam radiotherapy, RS = radiosurgery, SR = stereotactic radiotherapy, Gy = Gray, MRI = magnetic resonance imaging, CT = computed tomography.
* Data acquired after correspondence with the authors.
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a Originally, 15 patients were included in this study. However, we extracted data for 13 patients; two patients were excluded because of a follow-up duration of less than
12 months.
b Originally, 18 patients were included in this study. However, we extracted data for 17 patients; one patient was excluded because of a follow-up duration of less than
12 months.
c Originally, the authors described a cohort of 41 patients with JT paragangliomas. Twenty-three patients were treated surgically and excluded from our analyses. Two
patients were treated with combined therapy. Since it was unclear if local control was evaluated by radiological imaging, we also excluded data from these two patients from
our analyses. In 14 patients treated with RT as initial therapy, local control was evaluated by radiological imaging. For the purpose of this review, we extracted data from these
patients only.
d Originally, 19 patients were included in this study. However, one patient was followed up for less than 12 months. After correspondence with the authors, we were able to
exclude data from this patient from our analyses, except for these variables.
e The authors included 53 patients in their study. Twenty patients were treated surgically and therefore excluded from our analyses.
f Eighteen patients were included in this study. However, four patients received radiotherapy after total resection and could therefore not be analyzed for regression or
local control. Therefore, we excluded these four patients from our analyses, but were not able to exclude data from these patients for these variables.
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treated with stereotactic radiotherapy [29,34].
Median pre-radiotherapy tumor volume ranged from 2.8 to
9.5 cc. The effects of radiotherapy on tumor volume were assessed
by magnetic resonance imaging (MRI) in 53% of included studies
[8,14,28,29,31–34], by computed tomography (CT) in 13% [23,24]
and by both in 13% [27,30]. Three studies (20%) did not specify type
of imaging [22,25,26].Risk of bias assessment
Summary characteristics of the risk of bias assessment are
shown in Table 2. In 13 studies (87%) included patients were
explicitly described as consecutively exposed patients or as a ran-
dom sample of the inception cohort; in two studies this was un-
clear [30,32]. The intervention under study (i.e. radiotherapy)
was adequately described in all studies. The effect of radiotherapy
on tumor volume was adequately measured in 11 studies.
In two studies, we were not able to stratify the effects of radio-
therapy per treatment indication [22,29]. Actual loss to follow-upTable 2
Risk of bias assessment of included studies.
First author (year
of publication)
Consecutive patients or random
sample of inception cohort
Determination of
intervention adequately
reported
A
r
Lee (2011) [31] Yes Yes Y
Chen (2010) [25] Yes Yes U
Genc (2010) [14] Yes Yes Y
Hafez (2010) [28] Yes Yes Y
Tran Ba Huy
(2009) [30]
Unclear Yes Y
Henzel (2007)
[29]
Yes Yes Y
Lim (2007) [32] Unclear Yes Y
Gerosa (2006) [8] Yes Yes Y
Nguyen (2005)
[23]
Yes Yes Y
Zabel (2004) [34] Yes Yes Y
Elshaikh (2002)
[26]
Yes Yes U
Eustacchio
(2002) [27]
Yes Yes Y
Saringer (2002)
[33]
Yes Yes Y
Baillet (1990)
[22]
Yes Yes U
Scherrer (1986)
[24]
Yes Yes N
n.a. = not applicable, n.r. = not reported.
a Of 15 originally included patients.
b Data acquired after correspondence with the authors.
c Of 18 originally included patients.
d Of 41 originally included patients.
e Of 53 originally included patients.
f Of 18 originally included patients.was reported in 10 of 15 studies (67%). In only one of these 10
studies, loss to follow-up did not exceed 5% [27].Rate of tumor regression and local control: Meta-analysis
Table 3 gives an overview of reported regression and local con-
trol proportions of included studies. Reported treatment success
after radiotherapy was consistently good for local control, whereas
for tumor regression reported proportions varied considerably. For
radiosurgery (RS) as initial treatment, regression proportions var-
ied from 0.00 to 1.00. For RS as combined therapy these propor-
tions ranged from 0.00 to 0.50 and for RS as salvage therapy
from 0.00 to 1.00. For external beam radiotherapy (EBRT) as initial
treatment, regression proportions ranged from 0.00 to 0.64.
Local control proportions reported in individual studies ranged
from 0.67 to 1.00 for RS as initial treatment modality. For RS as
combined treatment only local control proportions of 1.00 were re-
ported and for salvage treatment, proportions of 0.89 to 1.00. For
EBRT as initial treatment modality, local control proportions
ranged from 0.86 to 1.00. When EBRT was used in a combined ordequacy of measurement of
egression and/or local control
Results stratiﬁed per
treatment modality
Number of patients
lost to follow-up (%)
es Yes n.r.
nclear Yes 5 (33)a
es Yes 1 (6)
es Yes n.r.
es n.a. n.r.
es No 1 (6)
es Yesb 2 (11)c
es Yes n.r.
es Yes 3 (7)d
es Yes 2 (9)
nclear n.a. n.r.
es Yes 0 (0)
es Yes 5 (9)e
nclear No 3 (17)f
o Yes 1 (10)
Table 3
Regression and local control rates per treatment modality and type of radiotherapy.
First author (rear of
publication)
Initial therapy Combined therapy (95% CI) Salvage therapy (95% CI)
Regression (95%
CI)
Local control (95%
CI)
Regression (95%
CI)
Local control (95%
CI)
Regression (95%
CI)
Local control (95%
CI)
Radiosurgery/stereotactic radiotherapy
Lee (2011) [31] 1.00 (0.66–1.00) 1.00 (0.66–1.00) n.a. n.a. 1.00 (0.48–1.00) 1.00 (0.48–1.00)
Chen (2010) [25] 0.33 (0.07–0.70) 0.67 (0.30–0.93) n.a. n.a. 1.00 (0.40–1.00) 1.00 (0.40–1.00)
Genc (2010) [14] 1.00 (0.59–1.00) 1.00 (0.59–1.00) n.a. n.a. 0.91 (0.59–1.00) 0.91 (0.59–1.00)
Hafez (2010) [28] 0.18a (0.02–0.52) 1.00 (0.72–1.00) n.a. n.a. 0.00a (0.00–0.84) 1.00 (0.16–1.00)
Henzel (2007) [29] 0.31b (0.11–0.59) 1.00b (0.79–1.00) n.a. n.a. 0.31b (0.11–0.59) 1.00b (0.79–1.00)
Lim (2007) [32] 0.31c (0.11–0.59) 1.00c (0.79–1.00) n.a. n.a. 0.25 (0.01–0.81) 1.00 (0.40–1.00)
Gerosa (2006) [8] 0.00 (0.00–0.71) 1.00 (0.29–1.00) n.a. n.a. 0.53 (0.28–0.77) 1.00 (0.80–1.00)
Zabel (2004) [34] 0.40a 0.12–0.74) 0.90 (0.56–1.00) n.a. n.a. 0.25a (0.05–0.57) 0.92 (0.62–1.00)
Elshaikh (2002) [26] n.a. n.a. n.a. n.a. n.r. 1.00 (0.59–1.00)
Eustacchio (2002) [27] 0.33a (0.01–0.91) 1.00 (0.29–1.00) 0.50a (0.12–0.88) 1.00 (0.54–1.00) 0.33a (0.07–0.70) 0.89 (0.52–1.00)
Saringer (2002) [33] 0.33 (0.04–0.78) 1.00 (0.54–1.00) 0.00 (0.00–0.71) 1.00 (0.29–1.00) 0.33 (0.04–0.78) 1.00 (0.54–1.00)
External beam radiotherapy
Tran Ba Huy (2009) [30] 0.27d (0.15–0.42) 0.96d (0.85–0.99) n.a. n.a. n.a. n.a.
Nguyen (2005) [23] 0.00 (0.00–0.23) 0.86 (0.57–0.98) n.a. n.a. n.a. n.a.
Elshaikh (2002) [26] n.a. n.a. n.a. n.a. n.r. 1.00 (0.48–1.00)
Saringer (2002) [33] 0.00 (0.00–0.34) 1.00 (0.66–1.00) 0.00 (0.00–0.34) 0.67 (0.30–0.93) n.a. n.a.
Baillet (1990) [22] 0.64e (0.31–0.89) 0.91e (0.59–1.00) 0.00 (0.00–0.71) 1.00 (0.29–1.00) 0.64e (0.31–0.89) 0.91e (0.59–1.00)
Scherrer (1986) [24] 0.00 (0.00–0.37) 1.00 (0.63–1.00) 0.00 (0.00–0.84) 1.00 (0.16–1.00) n.a. n.a.
n.a. = not applicable, n.r. = not reported.
a Data acquired after correspondence with the authors.
b Results could not be stratiﬁed for radiotherapy as initial or salvage therapy: percentages relate to 16 patients for whom follow-up data were available.
c Percentage relates to 16 tumors in 13 patients.
d Percentage relates to 45 tumors in 41 patients.
e Results could not be stratiﬁed for radiotherapy as initial or salvage therapy: percentages relate to 11 patients (6 receiving radiotherapy as initial treatment and ﬁve
receiving radiotherapy as salvage treatment).
Fig. 2. Meta-analysis.
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0.91 to 1.00, respectively.
Results of the random effects meta-analysis, stratiﬁed for type
of radiotherapy and treatment modality are displayed in Fig. 2.
Pooled regression proportions for radiosurgery as initial, combined
and salvage treatment were 21% (95% CI 9–69), 33% (95% CI 11–67)and 52% (95% CI 28–74), respectively. For external beam radiother-
apy, these proportions were 4% (95% CI 0–59), 0% (95% CI 0–23),
and 64% (95% CI 34–66).
Pooled local control proportions for radiosurgery as initial, com-
bined and salvage treatment were 99% (95% CI 74–100), 100% (95%
CI 66–100) and 99% (95% CI 90–99), respectively. For external
L.T. van Hulsteijn et al. / Radiotherapy and Oncology 106 (2013) 161–168 167beam radiotherapy, these proportions were 94% (95% CI 87–98),
79% (95% CI 51–93), and 94% (95% CI 66–99).Discussion
The present systematic review and meta-analysis aimed to as-
sess regression of tumor volume and local control rates in HNPGLs
treated with radiotherapy. Whereas regression rates diverged con-
siderably, both radiosurgery and external beam radiotherapy re-
sulted in excellent local control rates in jugulotympanic
paragangliomas.
The high local control rates shown in this meta-analysis are not
unexpected, taking into account the fact that about half of the
paragangliomas do not exhibit growth over time [3]. Our results
are in concordance with previously published reviews on local con-
trol rates after radiotherapy for HNPGLs, albeit slightly lower [10–
12]. This is probably due to the fact that we tried to abolish incor-
rectly positive local control rates by including only studies with a
P12 months follow-up period. Nevertheless, a signiﬁcant propor-
tion of the local control will reﬂect the natural course of the disease
rather than treatment effect. Moreover, only one study reported a
loss to follow-up <5%. This potential for selection bias may have
overestimated the effect of radiotherapy.
Included studies displayed heterogeneity in assessing the ef-
fects of radiotherapy. Although most studies described which
imaging techniques were used to determine treatment response,
precise volume measurement methods were often not reported.
Since paragangliomas are highly vascular tumors, blood ﬂow or
pressure may vary at different times when imaging studies are per-
formed [36]. Therefore, small decreases in tumor size on imaging
studies may not actually represent true regression of tumor vol-
ume. Since most studies determined any decrease of tumor volume
as regression, this may have led to an overestimation of regression
rates in our meta-analysis. On the other hand, three included stud-
ies determined regression as a P20% reduction of tumor volume
[8,29,30]. This variability in deﬁning regression may contribute
to the variety in regression rates. Future research on the effects
of radiotherapy on HNPGLs should apply uniform criteria for
changes in tumor size in order to objectively assess treatment
response.
In literature, an applied radiation dose of 45–50 Gy for EBRT
and a marginal radiation dose of at least 14 Gy for RS are recom-
mended to achieve local control of HNPGLs [37–39]. The average
applied radiation doses of included articles are well within this
range. The question arises whether a higher dose is needed to
achieve regression. Although no dose–effect correlation on tumor
shrinkage could be found by Gerosa et al. [8], none of the other
included articles addressed this issue and separate analyses
would be unfeasible due to the small numbers of included
patients.
With the present systematic review we aimed to assess the ef-
fects of radiotherapy in all types of HNPGLs. Yet, included studies
only comprised jugulotympanic paragangliomas and one thyroid
paraganglioma. Therefore, our results are not generalizable to
HNPGLs located elsewhere than the jugulotympanic region. The
fact that only few studies exist assessing the effect of radiotherapy
in carotid and vagal body tumors is probably due to the fact that
most authors consider surgery as the treatment option of choice
for cervical paragangliomas [40–42]. Our search resulted in only
one study which accurately evaluated the effects of radiotherapy
in cervical paragangliomas, reporting local control rates of 0.96
for radiotherapy as initial treatment and 0.88 for radiotherapy as
salvage therapy [43]. Unfortunately, this study included patients
with malignant HNPGLs and therefore was not eligible for inclu-
sion in this review.In our study, we were not able to take the indication for radio-
therapy as initial treatment into account. Since surgical treatment
is generally considered the reference standard for HNPGLs and ini-
tial treatment with radiotherapy is mostly used in HNPGL-patients
who are either poor surgical candidates due to old age or extensive
co-morbidity, or due to the localization of the tumor, e.g. the risk of
sacriﬁcing the vagal nerve in vagal body paragangliomas or intra-
cranial extension of jugulotympanic paragangliomas [23,30,44].
In this latter group, regression of tumor volume would be espe-
cially proﬁtable. However, special attention must be paid when
treating large intracranial tumors adjacent to the brainstem with
radiotherapy, since regression can be preceded by temporary tu-
mor volume progression due to development of edema [7,31].
Complications reported after the use of fractionated (external
beam) radiotherapy are xerostomia, stenosis of the external audi-
tory canal, alopecia, osteoradionecrosis of the temporal bone and
encephalopathy [45–47]. Also, one must take into consideration
the risk of inducing secondary malignancies in young patients after
treatment with radiotherapy, although in HNPGL-patients this risk
is reported to be 0.3% [48]. In EBRT studies included in our review,
mucositis and nausea were reported as acute side effects and xero-
stomia, serous otitis media and vertigo as late side effects of radio-
therapy [22,23,30]. In studies concerning stereotactic radiotherapy,
transient low-grade xerostomia, nausea, taste irritation, middle ear
effusion, vertigo, headache and mucositis were reported as well as
a maxillary bone abscess [29,34].
Studies in radiosurgery yielded higher regression and local con-
trol rates than EBRT studies, indicating that radiosurgery is a more
effective treatment than EBRT for jugulotympanic paragangliomas.
A beneﬁt of radiosurgery over fractionated radiotherapy is that the
patient is treated in a single session with a reduced total radiation
volume. In radiosurgery studies included in our review, two pa-
tients sustained transient complications. One patient’s pre-existing
swallowing disorder worsened 1 month after irradiation and the
second patient developed ipsilateral incomplete facial nerve palsy
12 months after irradiation [33]. None of the included studies re-
ported secondary malignancies.Conclusions
According to the available evidence, radiotherapy seems to be a
valuable treatment in establishing local control in patients with
jugulotympanic paragangliomas. The effects of radiotherapy on
regression of tumor volume remain ambiguous, although the data
suggest that regression is achieved at least in some patients. For a
more precise determination of the effects of radiotherapy in
HNPGL-patients, prospective, long-term follow-up studies with
accurate radiologic evaluation and clear deﬁnitions of change in tu-
mor volume are warranted.Conﬂicts of interest statements
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